Applied Immune Sciences Inc., Rhône-Poulenc Rorer deal

AISX shareholders tendered 7 million shares (97.8 percent of the shares not held by RPR) at $11.75, completing the acquisition of AISX by RPR (see BioCentury Oct. 23). AISX will become an indirect, wh...